- Conditions
- Dermatomyositis, Polymyositis
- Interventions
- M5049 high dose, Placebo
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced May 22, 2026, 12:11 AM EDT